RESEARCH MONOGRAPH · KDC-MN-321

Cannabigerol (CBG)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

61/100

Underrated phytocannabinoid with cleaner non-CB receptor pharmacology than CBD, evidence still thin

CBG is the 'mother cannabinoid' the chemistry textbooks talk about, because it's the biosynthetic precursor to THC, CBD, and CBC in the cannabis plant via the various synthase enzymes. Mature plants convert almost all of it forward so naturally occurring CBG percentages are usually under 1%, which is why it stayed obscure for decades and only became accessible once industrial extraction and selective breeding scaled up.

Mechanism is honestly interesting and meaningfully different from CBD. CBG is a more potent alpha-2 adrenergic agonist than most cannabinoids and one of the stronger 5-HT1A antagonists in the class. It also hits TRPM8 and TRPA1, and there's growing evidence for direct CB1 partial agonism that CBD doesn't really show. Cascio and colleagues have most of the receptor-pharmacology work worth reading.

The preclinical literature is thinner than CBD by an order of magnitude but interesting. Antiinflammatory effects in colitis models (Borrelli 2013, Biochem Pharmacol), neuroprotective signal in Huntington's models (Valdeolivas), and some appetite-stimulant data that maps onto the alpha-2 mechanism. None of this has translated to human RCTs yet at any meaningful scale, which is the main caveat.

What we like: cleaner receptor pharmacology than CBD in the sense that the non-CB targets are more selective and the dose-response curves are tighter. For research questions where you want to probe alpha-2 or 5-HT1A in an endocannabinoid-system context it's actually a useful tool. The TRP-channel activity makes it interesting in pain biology.

What we dont like is the consumer-market situation. CBG products are flooding into the same dose-mismatched, poorly-QC'd retail space that swallowed CBD, except now with even less evidence behind the claims. And the price-per-gram for high-purity material is still meaningfully higher than CBD because the biomass yields are low.

Sourcing: high-purity crystalline CBG is available from a handful of reliable suppliers, HPLC verification is necessary because partial conversion to other cannabinoids during extraction is a real QC issue. Want the certificate showing residual solvents and the THC content close to zero.

Worth keeping an eye on. Thin evidence base but interesting pharmacology and may end up being a more useful research tool than CBD for specific questions.

Evidence: 45
Mechanism: 65
Reliability: 55
Safety: 80
Sourcing: 72
Value: 55
Signal: 55
Staying power: 60

Plain-language summary Intrigue 48 / 100

Cannabigerol is the biosynthetic parent of THC and CBD inside the cannabis plant. Mature plants typically convert nearly all of it into those downstream cannabinoids, leaving less than 1 percent CBG in finished flower. It is non-intoxicating and engages a different mix of targets than CBD, including weak partial agonism at CB1 and CB2, alpha-2 adrenergic agonism, and PPAR-gamma activation. Preclinical work suggests anti-inflammatory and neuroprotective effects, with particular interest in inflammatory bowel disease. Human clinical evidence remains limited and most consumer products rely on extrapolation from animal and cell studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Phytocannabinoid (CB receptor weak agonist)

A non-intoxicating phytocannabinoid; the metabolic precursor of THC and CBD; investigated for inflammation, neuroprotection, and inflammatory bowel disease.

Abstract

Cannabigerol (CBG; CAS 25654-31-3; molecular formula C21H32O2; molecular weight 316.48) is a non-intoxicating phytocannabinoid from Cannabis sativa. The compound is the biosynthetic precursor of THC, CBD, and CBC in plants; mature plants typically contain less than 1 percent CBG owing to enzymatic conversion to these downstream cannabinoids. Mechanism: CB1 and CB2 partial agonism (weaker than THC), alpha-2 adrenergic agonism, 5-HT1A antagonism (opposite of CBD), and PPAR-gamma agonism. The mechanism profile is distinct from both THC and CBD. Preclinical evidence supports anti-inflammatory effects in colitis models, neuroprotection in Huntington and Parkinson models, and antibiotic activity against MRSA. Human clinical trial data are sparse; the compound is sold as a supplement with limited regulatory guidance. Plasma pharmacokinetics are similar to other phytocannabinoids: high lipophilicity, hepatic metabolism via CYP enzymes, long terminal half-life. Used as a non-intoxicating phytocannabinoid in inflammation and neuroprotection research.

Mechanism of action

CB1/CB2 partial agonism (weaker than THC); alpha-2 adrenergic agonism; 5-HT1A antagonism; PPAR-gamma agonism.

Reported research dose ranges

Supplement use 5 to 50 mg in the published literature; clinical trial doses up to 600 mg.

References

Borrelli F, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol 2013.
Valdeolivas S, et al. Neuroprotective properties of cannabigerol in Huntington's disease. Neurotherapeutics 2015.
Appendino G, et al. Antibacterial cannabinoids from Cannabis sativa. J Nat Prod 2008.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-321

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Cannabigerol (CBG)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs